BIIB Stock Price History and Quote Analysis: Insights for Investors
Biogen Inc.
Stock Price Today
Biogen Inc. (BIIB) stock declined over -0.71%, trading at $182.04 on NASDAQ, down from the previous close of $183.34. The stock opened at $182.73, fluctuating between $181.31 and $183.43 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 7570 |
| Beta | -0.057 |
| Sales or Revenue | $9.84B |
| 5Y Sales Change% | 0.035% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently Asked Questions
Biogen Inc. (NASDAQ: BIIB) stock price is $182.04 in the last trading session. During the trading session, BIIB stock reached the peak price of $183.43 while $181.31 was the lowest point it dropped to. The percentage change in BIIB stock occurred in the recent session was -0.71% while the dollar amount for the price change in BIIB stock was -$1.30.
The NASDAQ listed BIIB is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Biogen Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Nicole Murphy
Head of Pharmaceutical Operations & Technology
Dr. Sanjay Jariwala
Senior Vice President of Worldwide Medical
Ms. Robin C. Kramer
Senior Vice President & Chief Accounting Officer
Mr. Adam Keeney Ph.D.
Executive Vice President & Head of Corporation Devel.
Dr. Anabella Villalobos Ph.D.
Head of Biotherapeutics & Medicinal Sciences
Dr. Mahalakshmi Radhakrishnan M.D.
Chief Medical Officer & Group Senior Vice President
Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corporation Affairs
Dr. Ginger Gregory
Executive Vice President & Chief HR Officer
Mr. Christopher A. Viehbacher
Pres, Chief Executive Officer & Director
Mr. Michael R. McDonnell CPA
Executive Vice President & Chief Financial Officer
Mr. Michael Hencke
Executive Director of Investor Relations & Investor Relations Team
Mr. Charles E. Triano
Senior Vice President & Head of Investor Relations
Ms. Susan H. Alexander Esq.
Executive Vice President, Chief Legal Officer & Sec.
Dr. Priya Singhal M.D., M.P.H.
Executive Vice President, Head of Devel. and Interim Head of Research, Global Safety & Regulatory Sciences
Ms. Alisha A. Alaimo
Pres & Head of North America
BIIB's closing price is 0.47% higher than its 52-week low of $181.31 where as its distance from 52-week high of $269.43 is -31.95%.
Number of BIIB employees currently stands at 7,570.
Official Website of BIIB is: https://www.biogen.com
BIIB could be contacted at phone 617 679 2000 and can also be accessed through its website. BIIB operates from 225 Binney Street, Cambridge, MA 02142, United States.
BIIB stock volume for the day was 542.99K shares. The average number of BIIB shares traded daily for last 3 months was 1.07M.
The market value of BIIB currently stands at $26.52B with its latest stock price at $182.04 and 145.66M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com